Prospective Cohort for Tumor Bed Boost Radiotherapy in HER2 Positive Breast Cancer

Condition(s) studied

Investigational drug(s) / intervention(s)

Whole breast irradiation +/- tumor bed boost: Postoperative whole breast irradiation (3D-conformal radiation therapy or IMRT) with or without tumor bed boost (sequential or simultaneous integrated boost)

Study summary

The purpose of this study is to analyze treatment outcomes related to tumor bed boost of postoperative radiation therapy in patient with HER2+ breast cancer who underwent breast conserving surgery.

The main questions it aims to answer are:

* 7-year ipsilateral breast tumor recurrence
* 7-year disease-free survival
* 7-year locoregional recurrence
* 7-year overall survival
* Adverse events of radiation therapy

Participants will be assessed by multi-dimensional methods after radiation therapy:

* Assessment for the disease status (disease-free or recurrence) including physical and radiologic examination
* Assessment for the adverse events according to CTCAE version 5.0

Eligibility

Primary outcome measure(s)

• Ipsilateral breast tumor recurrence — 7 years from the start of the postoperative radiation therapy
  The event for ipsilateral breast tumor recurrence (IBTR) was defined as any breast tumor recurrence in irradiated breast.

Trial sites (1)

More Samsung Medical Center trials in South Korea

Other trials for the same condition